-
December 6, 2023 Lupin Receives Approval from U.S. FDA for Varenicline Tablets
-
December 1, 2023 Lupin Launches Turqoz®(Norgestrel and Ethinyl Estradiol) Tablets USP in the United States
-
November 23, 2023 Lupin Receives Approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.07%
-
November 23, 2023 Lupin Receives Tentative Approval from U.S. FDA for Canagliflozin Tablets
-
November 23, 2023 Lupin Launches World’s First Fixed-dose Triple Combination Drug, Vilfuro-G® for COPD Management in India
-
November 21, 2023 Lupin Receives Approval from U.S. FDA for Pitavastatin Tablets
-
November 21, 2023 Lupin Receives Tentative Approval from U.S. FDA for Dapagliflozin Tablets
-
November 17, 2023 Lupin Receives Approval from U.S.FDA for Ganirelix Acetate Injection
-
November 10, 2023 Lupin and Amman Pharma Sign Exclusive Licensing and Supply Agreement for Ranibizumab Biosimilar
In this section
Media Contacts
-
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications